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Abstract
Recommendations by the International Society of Urologic Pathology and 2016 World
Health Organization blue book propose the use of a ﬁve-tiered prostate cancer (PCa)
grading system. The ﬁve prognostic grade groupings (PGGs) ranging from 1 to 5 are
deﬁned as Gleason grades 6, 3 + 4, 4 + 3, 8, and >8, respectively. Recent work suggests
that each group is associated with a distinct risk of biochemical PCa recurrence. In this
study, we sought genomic support for PGGs using whole-exome and whole-genome
sequencing data for 426 clinically localized PCas treated by radical prostatectomy. After
adjustment for tumor purity for the sequencing data, we observed a signiﬁcant fre-
quency increase in genomic ampliﬁcations and deletions (p = 0.013) and in nonsynon-
ymous point mutations (p = 0.008) with increasing risk group. Interestingly, PGG1 (low
risk) was entirely haploid, whereas PGG2–5 exhibited increasing polyploidy frequency.
Principal component analysis of genomic proﬁles revealed that PGG1, PGG2, and PGG3
represent distinct classes, but PGG4 and PGG5 exhibit genomic similarity. Together,
these observations for the largest PCa genomic data set to date provide support for
increasing genomic alterations with increasing PGG. This is the ﬁrst genomic correlation
of the PGG system. Future work will need to explore the clinical utility of PGGs in
prospective studies with long-term follow-up.
Patient summary: Gleason grading for prostate cancer provides important information
for guiding clinical care. A new proposal by leading pathologists favors translating
Gleason grades into ﬁve risk categories. In this study, a comprehensive analysis of the
largest genomic data set on prostate cancer to date, we demonstrate molecular support
for this new ﬁve-tiered system.
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correlate acinar tumor growth patterns with patient clinical
outcomes [1]. This system is consistently one of the best
independent predictors of clinical outcome for prostate
cancer (PCa). Contemporary clinical practice has reduced
the system to distinguishing two key patterns: tumors with
and without Gleason pattern 4 or 5 (high-grade) disease,
associated with the worst clinical outcomes. The system
originally used a Gleason range of 2–10, going from low (2–
6), to intermediate (7) and high (8–10) Gleason grade. More
recently, the scale has shrunk to scores that now range from
6 to 10; it is exceptionally rare to see Gleason scores of 2–5
with contemporary grading. In addition to educational
improvements in Gleason scoring, the advent of immuno-
histochemistry for basal cells has virtually eliminated
diagnosis of Gleason patterns 1 and 2 [2]. In 2013, Epstein
and colleagues [3] originally proposed reducing this system
to five prognostic risk categories. More recently, a larger
validation study supported the distinct risk of PSA
biochemical recurrence based on each risk category
[4]. Epstein and others performed a retrospective analysis
of more than 19 000 consecutive men with localized PCa
treated by radical prostatectomy between 2005 and 2014 at
the Cleveland Clinic, Memorial Sloan Kettering Cancer
Center, Johns Hopkins Hospital, University of Pittsburgh,
and Karolinska Institute. They reported 5-yr biochemical
risk-free survival for prognostic grade groups (PGGs) of
97.5% for PGG1, 93.1% for PGG2, 78.1% for PGG3, 63.6% for
PGG4, and 48.9% for PGG5. On the basis of these data and
discussions by expert genitourinary pathologists, urolo-
gists, oncologists, and other clinicians who care for PCa
patients, a consensus group convened by the International
Society of Urological Pathology proposed these risk
categories for the new 2016 World Health Organization
PCa reporting guidelines [2]. The PGG system complements
theGleason score and helps to emphasizewhere scores fit in
a proposed risk stratification schema.Most importantly, the
PGG system emphasizes that a Gleason score of 6 corre-
sponds to low-risk cancer. This will have important
implications for patients as they consider treatment options
among surgery, radiation therapy, and active surveillance.
It follows that PGGs with increasing risk could also have
genomic correlates. With the emergence of large, publicly
available genomic data sets for PCa, we askedwhether these
proposed risk strata correspond to distinct genomic groups.
To this end, we compiled a data set comprising 426 tumor/
normal pairs frommen with clinically localized PCa treated
with radical prostatectomy as monotherapy. The tumors
were subjected to either whole-exome or whole-genome
sequencing [5–7]. Supplementary Table 1 lists demographic
data and the Gleason score breakdown. This data set is the
largest genomic PCa data set to date.
A moderate increase in median prostate-specific antigen
(PSA) at diagnosis was observed with increasing risk
category (linear regression, p = 0.009), whereas no associa-
tion with median age at diagnosis was detected (linear
regression, p = 0.3189). After adjustment for tumor poly-
ploidy and purity on a sample basis [8] to allow fair
comparison across tumors with diverse cellularity, weanalyzed tumor genomic characteristics across risk groups
(Supplementary Table 2). The overall number of nonsynon-
ymous somatic mutations slightly increased across risk
strata, reaching higher statistical significance when com-
paring lower (PGG1 and PGG2) with higher (PGG3, PGG4,
and PGG5) risk groups (Wilcoxon-Mann-Whitney test,
p = 1.01  104). Overall, more abundant somatic copy
number alterations (gains and losses) were observed with
increasing PGG (Fig. 1).
To investigate aberration frequency across PGGs on a
gene basis, we focused on a set of 880 cancer genes
(Supplementarymaterial). For each aberrant genewe tested
possible increasing, decreasing, invariant and mixed (or
parabolic) trends (Supplementary material). Examples are
shown in Figure 2A, where MYC amplification, TP53
deletion, and 21q22.3 deletion near TMPRSS2 represent
increasing, mixed, and invariant frequencies, respectively.
Of the 389 recurrently amplified genes (ie, increased
somatic DNA copy number) in the data set, 91% exhibit
increasing DNA copy number amplification frequency
across PGGs; thus, their incidence correlates with higher
PGG. This includes NCOA1 (9–50% for PGG1–5) and MYC
family members, with MYC reaching the highest frequency
in PGG5 (45.5%), followed by MYCN (13.6%) and MYCL
(6.8%). A similar situation was observed for 35% of the
756 recurrently deleted genes, whereas a large fraction
(56%) exhibited an invariant trend across risk groups
(Fig. 2B). Genomic regions with the steepest increase in
deletion frequencies across PGGs included areas on 13q32
and 18q21. Interestingly, of the few recurrent somatic point
mutations in hormone-naı¨ve PCa, only TP53 incidence
increased across the PGGs (PGG1, 0%; PGG2, 7%; PGG3, 8%;
PGG4, 10%, and PGG5, 9%). Complete results for the
frequency trend analysis are listed in Supplementary
Table 3. There was similar incidence across the groups
for the most common aberrations in localized PCa, ERG
rearrangement in terms of structural variants and SPOP
mutations for single base changes. Frequency trend analysis
was also explored for gene aberration within subsets of
tumors defined by ERG rearrangement or SPOP mutation.
The results are in line with the findings for the whole data
set (Supplementary Figs. 1 and 2). Consistent with previous
studies, while the number of aberrant genes slightly
increased with patient age (linear regression using age
quartiles, p = 0.027), ERG rearrangement was significantly
enriched in the youngest group (58% for the lowest and 32%
for the highest age quartile; hypergeometric test,
p = 0.0045) [9].
PGG1, defined as Gleason score 6 (3 + 3), is the critical
class to understand at a molecular level. Clinically, PGG1
patients with PSA <10 ng/ml and negative digital rectal
examination (DRE) results are suitable candidates for active
surveillance. The genomic analysis of PGG1 clearly confirms
the presence of somatic aberrations (eg, the incidence of
interstitial deletion between TMPRSS2 and ERG is20%) but
reveals that none of the tumors exhibited polyploidy, a
characteristic finding in 1.3% of PGG2, 3.1% of PGG3, 3.5% of
PGG4, and 9.1% for PGG5 tumors (linear regression,
p = 0.02), and hardly any amplification (Fig. 1).
[(Fig._1)TD$FIG]
Fig. 1 – Landscape of somatic copy number alterations from 426 prostate cancer cases ordered by prognostic grading group from 1 (low) to 5 (high).
Blue denotes deletions; red denotes amplifications.
[(Fig._2)TD$FIG]
Fig. 2 – (A) Examples of aberration frequencies across prognostic grading groups (PGGs) on a gene basis. MYC amplification, TP53 deletion and 21q22.3
deletion near TMPRSS2 represent increasing, mixed, and invariant frequencies, respectively. (B) Summaries of frequency trends detected for copy
number alterations on a gene basis across PGGs. (C) Number of aberrant genes per patient tumor across PGGs. Principal component analysis
demonstrates that PGG4 and PGG5 have significant overlap (inset).
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genes to distinguish PGGs. Focusing on the merged gene set
obtained from the top 100 aberrant genes per PGG
(resulting in 147 genes; Fig. 2C) and applying principal
component analysis to the whole data set, we observed no
significant distinction between PGG4 and PGG5, whereas
PGG1 appears to be clearly distinct from the other
categories (Fig. 2C inset).In summary, the proposed new risk categories take into
account the reality of clinical practice in 2015. Although
PGGs are not initially meant to replace Gleason scores, they
provide a useful clinical perspective in discussing risk. Using
emerging genomic data, the current study supports the
notion that PGGs also correspond to genomic events.
Importantly, the lowest risk group (PGG1) supports
favorable genomic features such as a lack of polyploidy
E U RO P E AN URO LOGY 6 9 ( 2 0 1 6 ) 5 5 7 – 5 6 0560and fewer driver mutations. PGG1 patients with low
PSA and negative DRE represent the type of patients who
may be ideal for active surveillance. Interestingly,
PGG4 and PGG5 do not significantly differ from one
another. However, recent clinical studies suggest that
these groups do have different clinical outcomes [10]. It is
possible that [2_TD$DIFF]epigenetic changes or other alterations that
are yet to be described are responsible for the clinical
difference.
One major limitation in the development of the PGG
system is that PSA biochemical recurrence was used to
determine levels of risk. Recent work does not support PSA
recurrence as a surrogate for disease progression [11]. There-
fore, future studies will be needed in the setting of active
surveillancewith long-term observations to help in support-
ing the PGG system and potential genomic correlates of risk.
Ultimately, if verified over time with additional studies, the
PGG system could replace Gleason scores.
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